Micro Imaging Technology, developer of the patented MIT 1000, an optically based software-driven system that can identify pathogenic bacteria and complete an identification test, has entered into a collaboration agreement with the Northern Michigan University (NMU) Department of Biology to expand MIT 1000 technology application.
MMTC and NMU will work together to use MIT 1000, which can identify pathogenic bacteria in an average three minutes time, to also rapidly and cost-effectively identify and differentiate Staphylococcus aureus(S. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA).
“Being able to quickly identify if a patient has an S. aureus infection, and whether or not that S. aureus is MRSA, a strain of S. aureus resistant to certain antibiotics would be extremely useful in dictating the proper course of treatment for that patient, and ultimately increase the likelihood of a successful patient outcome,” Dr. Josh S. Sharp, Ph.D., assistant professor at the NMU Department of Biology and director of the NMU portion of the collaborative research, stated in the news release.
MMTC Chief Scientist Dr. David Haavig is the program director of the effort and will lead the company’s team in the collaboration.
“We are extremely pleased to be working with Dr. Sharp and his staff on this project,” said Haavig, who MMCT says was integral to the development of MIT 1000. “We are confident that this collaborative effort will be highly successful and the result of our teamwork and the clinical implications for this technology may very well prove to be immeasurable.”
Scientists from both parties are currently gathering preliminary data and developing collaborative research proposals to obtain funding for further research.
For more information visit www.micro-identification.com
Let us hear your thoughts below: